Indian drugmaker Dr. Datsons Labs has told the Bombay Stock Exchange it expects a $17 million investment from a Belgium-based nutraceutical maker which wants access to one of its API facilities. According to VCCircle, the structure of the deal was not disclosed in the filing but Dr. Datsons said Eubage Laboratory intends to invest in its manufacturing operations and also outlicense 20 of its products to the Indian drugmaker.
When Gulf Pharmaceutical decided to invest about $10 million to build a pharma manufacturing plant in Ethiopia some years back, it seemed like a big risk, a company executive recently acknowledged. With a solid dose plant doing well, the United Arab Emirates-based company is ready to invest 5 times that in a sterile injectable drug manufacturing plant.
Growth in areas like antibody drug conjugates helped Lonza's Pharma & Biotech segment turn in more than 15% growth for the year and, in turn, helped the entire company realize one of its recovery goals a full year ahead of schedule, the Swiss company said Wednesday.
When Novartis announced plans to hand off its consumer health operations to a joint venture with GlaxoSmithKline, the companies said they figured they could save a boatload of money in "synergies." It looks like a small part of that will come from closing a Novartis plant in Puerto Rico that makes consumer and veterinary products, shedding 270 jobs in the process.
Boehringer Ingelheim is considering severing more of its ties to drug production in Ohio. The latest asset to go up for sale is Roxane Labs, a Columbus, Ohio-based generics business that also produces some of Boehringer's patent-protected drugs.
Piramal Pharma Solutions is lining up a $40 million investment to ensure its facilities have the equipment and technologies to keep clients and regulators happy.
Hospira is making cuts to its manufacturing network. The Lake Forest, IL-based drugmaker plans to close its facility in Clayton, NC, in June at a cost of up to 250 jobs and $15 million in severance payments and other employee-related costs.
AMRI has extended a buying streak to build up its contract manufacturing capabilities, adding to its injectable drug operations in the process. The New York-based company will lay out $60 million to buy two facilities from drug development specialist Aptuit.
Cambridge Major Laboratories (CML) will spend $20 million to expand its manufacturing plant, R&D operations and administrative offices in Germantown, WI.
Japan's Fujifilm has completed the purchase of not quite 50% of vaccine specialist Kalon Biotherapeutics, making it a key player in the U.S. pandemic defenses.